Sugar tracking study aims to unlock breast Cancer's fuel secrets
NCT ID NCT05736367
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study looks at how hormone receptor positive/HER2 negative breast cancer uses glucose and other nutrients for energy. Sixteen participants with early-stage breast cancer will receive a special labeled sugar infusion before surgery. Researchers will then analyze tumor and healthy tissue samples to map metabolic pathways, which could help identify new treatment targets in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
U-13C-glucose (a special labeled sugar given by infusion to track how tumors use energy)
What this could lead to
If successful, this study could reveal new metabolic targets for treating HR+/HER2- breast cancer, potentially leading to more effective therapies.
What could go wrong
This is a very small pilot study (16 people) with no treatment being tested. It only aims to understand metabolism, not to cure or control the disease. Results may not lead to any practical changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RWJBarnabas Health
NOT_YET_RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••